Fluid-based prognostication in n-AMD: Type 3 macular neovascularisation needs an analysis in isolation

Ashish Sharma; Nikulaa Parachuri; Nilesh Kumar; Francesco Bandello; Baruch D. Kuppermann; Anat Loewenstein; Carl Regillo; Usha Chakravarthy

doi:10.1136/bjophthalmol-2020-318128

Fluid-based prognostication in n-AMD: Type 3 macular neovascularisation needs an analysis in isolation

Ashish Sharma^*, Nikulaa Parachuri, Nilesh Kumar, Francesco Bandello, Baruch D. Kuppermann, Anat Loewenstein, Carl Regillo, Usha Chakravarthy

^*Corresponding author for this work

Ophthalmology

Research output: Contribution to journal › Editorial

Original language	English
Pages (from-to)	297-298
Number of pages	2
Journal	British Journal of Ophthalmology
Volume	105
Issue number	3
DOIs	https://doi.org/10.1136/bjophthalmol-2020-318128
State	Published - 1 Mar 2021

Keywords

eye (globe)
imaging
macula
retina

Access to Document

10.1136/bjophthalmol-2020-318128

Cite this

@article{b3c02a2f00a64f9ba3e37ae50de61952,

title = "Fluid-based prognostication in n-AMD: Type 3 macular neovascularisation needs an analysis in isolation",

keywords = "eye (globe), imaging, macula, retina",

author = "Ashish Sharma and Nikulaa Parachuri and Nilesh Kumar and Francesco Bandello and Kuppermann, {Baruch D.} and Anat Loewenstein and Carl Regillo and Usha Chakravarthy",

note = "Funding Information: Competing interests AS—consultant: Novartis India, Allergan Global, Intas India, Bayer India. NP: none. NK: none. FB—consultant: Allergan, Bayer, Boehringer Ingelheim, Fidia Sooft, Hoffmann-La Roche, Novartis, NTC Pharma, Sifi, ThromboGenics, Zeiss. BDK—clinical research: Alcon, Alimera, Allegro, Allergan, Apellis, Clearside, Genentech, GSK, Ionis, jCyte, Novartis, Regeneron, ThromboGenics; consultant: Alimera, Allegro, Allergan, Cell Care, Dose, Eyedaptic, Galimedix, Genentech, Glaukos, Interface Biologics, jCyte, Novartis, Ophthotech, Regeneron, Revana, Theravance Biopharma. Dr Kuppermann acknowledges an unrestricted grant from Research to Prevent Blindness to the Gavin Herbert Eye Institute at the University of California, Irvine. AL—consultant: Allergan, Novartis, Roche, Notal Vision, FiorSightsLabs, Beyeonics, Bayer Healthcare. CR—consultant: Allergan, Chengdu Kanghong, Genentech/Roche, Novartis, Kodiak, Notal, Merck, Shire-Takeda, Adverum, Graybug, Eyepoint; research support: Allergan, Chengdu Kanghong, Genentech/Roche, Novartis, Kodiak, Iveric, Adverum. UC has received grants from the National Institute for Health Research and Novartis; personal fees from Allergan, Bayer, Novartis, and Roche; and is a data safety and monitoring board member for Bayer.",

year = "2021",

month = mar,

day = "1",

doi = "10.1136/bjophthalmol-2020-318128",

language = "אנגלית",

volume = "105",

pages = "297--298",

journal = "British Journal of Ophthalmology",

issn = "0007-1161",

publisher = "BMJ Publishing Group",

number = "3",

}

TY - JOUR

T1 - Fluid-based prognostication in n-AMD

T2 - Type 3 macular neovascularisation needs an analysis in isolation

AU - Sharma, Ashish

AU - Parachuri, Nikulaa

AU - Kumar, Nilesh

AU - Bandello, Francesco

AU - Kuppermann, Baruch D.

AU - Loewenstein, Anat

AU - Regillo, Carl

AU - Chakravarthy, Usha

N1 - Funding Information: Competing interests AS—consultant: Novartis India, Allergan Global, Intas India, Bayer India. NP: none. NK: none. FB—consultant: Allergan, Bayer, Boehringer Ingelheim, Fidia Sooft, Hoffmann-La Roche, Novartis, NTC Pharma, Sifi, ThromboGenics, Zeiss. BDK—clinical research: Alcon, Alimera, Allegro, Allergan, Apellis, Clearside, Genentech, GSK, Ionis, jCyte, Novartis, Regeneron, ThromboGenics; consultant: Alimera, Allegro, Allergan, Cell Care, Dose, Eyedaptic, Galimedix, Genentech, Glaukos, Interface Biologics, jCyte, Novartis, Ophthotech, Regeneron, Revana, Theravance Biopharma. Dr Kuppermann acknowledges an unrestricted grant from Research to Prevent Blindness to the Gavin Herbert Eye Institute at the University of California, Irvine. AL—consultant: Allergan, Novartis, Roche, Notal Vision, FiorSightsLabs, Beyeonics, Bayer Healthcare. CR—consultant: Allergan, Chengdu Kanghong, Genentech/Roche, Novartis, Kodiak, Notal, Merck, Shire-Takeda, Adverum, Graybug, Eyepoint; research support: Allergan, Chengdu Kanghong, Genentech/Roche, Novartis, Kodiak, Iveric, Adverum. UC has received grants from the National Institute for Health Research and Novartis; personal fees from Allergan, Bayer, Novartis, and Roche; and is a data safety and monitoring board member for Bayer.

PY - 2021/3/1

Y1 - 2021/3/1

KW - eye (globe)

KW - imaging

KW - macula

KW - retina

UR - http://www.scopus.com/inward/record.url?scp=85097404743&partnerID=8YFLogxK

U2 - 10.1136/bjophthalmol-2020-318128

DO - 10.1136/bjophthalmol-2020-318128

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.editorial???

C2 - 33293272

AN - SCOPUS:85097404743

SN - 0007-1161

VL - 105

SP - 297

EP - 298

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

IS - 3

ER -

Fluid-based prognostication in n-AMD: Type 3 macular neovascularisation needs an analysis in isolation

Keywords

Access to Document

Other files and links

Cite this